Home > Healthcare > Drug Device Combination > Therapeutic Systems > Oncolytic Virotherapy Market

Oncolytic Virotherapy Market Trends

Report ID: GMI9645
Published Date: May 2024
Report Format: PDF

Download Free Sample

Oncolytic virotherapy Market Trends

The market is experiencing a growing interest in combination therapy. Vendors are combining oncolytic virotherapy with other cancer immunotherapy, such as immune checkpoint inhibitors, to enhance anti-tumor immune responses and overcome resistance mechanisms.
Combination therapies are gaining interest of researchers to enhance immune system activation and enhance treatment results across various types of cancer. For instance, according to a study published by National Center for Biotechnology Information in January 2023, combining oncolytic viruses with anti?checkpoint antibodies can lead to improved antitumor responses. As a result, increasing interest from researchers in combination therapy is expected to drive the market growth during the forecast period.
Moreover, global market is also experiencing growth due to rising clinical trial engagement and commercialization initiatives extending beyond conventional developed markets. Emerging regions in Asia and Latin America have become key contributors to the advancement and acceptance of oncolytic virotherapy.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global oncolytic virotherapy industry size was valued at USD 20.1 million in 2023 and is anticipated to showcase growth at 26.9% CAGR from 2024–2032 due to the rising incidence of cancer and increasing investments for developing new oncolytic virotherapies.

The solid tumors segment in the market accounted for USD 12.1 million in 2023 due to the high prevalence of breast, prostate, and lung cancer.

North America oncolytic virotherapy market is expected to reach USD 68.9 million by 2032 due to robust research infrastructure, early adoption of innovative therapies, and increasing awareness among people.

Amgen Inc., BioVex, Inc., Circio Holding ASA, Daiichi Sankyo Company, DNAtrix, Lokon Pharma AB, Medigene AG, Oncolytics Biotech Inc., PsiOxus Therapeutics, Shanghai Sunway and Biotech Co., Ltd., among others.